#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

. !.

PCT/EP2003/01337#10/539516 International Application No. International Filing Date November 27, 2003 Priority Date(s) Claimed December 17, 2002 Applicant(s) (DO/EO/US) Timo HEINRICH et al. Title: N-(INDOLETHYL-)CYCLOAMINE COMPOUNDS INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees  $\bowtie$ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR  $\boxtimes$ before the mailing of a first substantive office action (including after filing of an RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

# JC05 Rec'd PCT/PTO 17 JUN 2005 10/539516

		is acco	empanied by:	
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR	
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).	
			R. § 1.97(d), this information disclosure statement is filed after the mailin lowing actions which have not been withdrawn:	g
		a final	action under 37 C.F.R. § 1.113;	
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);	
		OR a r	notice of allowance under 37 C.F.R. § 1.311;	
	AND i	is filed	on or before payment of the issue fee; AND is accompanied by:	
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of under 37 C.F.R. § 1.17(p).	f
Staten	nents Uı	nder 37	C.F.R. 1.97(e)	
			Each item of information contained in this information disclosur statement was cited in a communication from a foreign patent office in counterpart foreign application having a mailing date not more than thre months prior to the filing date of this information disclosure statement; or	a e
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorne after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designate in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.	t y s d
Cited	Materia	<u>ls</u>		
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120 or application Serial No, on Form 892 by the Examiner and/or Form y the applicant; see 37 C.F.R. § 1.98(d).	•
	$\boxtimes$	-	of materials listed but not attached were cited in an international searc dated April 19, 2004.	h
		Not re	quired by 37 CFR § 1.98.	
		Copies	of the materials listed are attached (except for the foregoing).	

## JC05 Rec'd PCT/PTO 17 JUN 2005 10/539516

Non-E	nglish]	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	$\boxtimes$	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>
		<ul> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> </ul>
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application L = cited for another reason
		& = publication of member of same patent family
	$\boxtimes$	Translation of other relevant information on foreign search report
		In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other	Informa	<u>ition</u>
Pavme	ent of F	ees Due (If Any):
		ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

#### 10/539516 JC05 Rec'd PCT/PTO 17 JUN 2005

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3025

Date: June 17, 2005

AJZ:aap

K:\Merck\Merck 3000 - 3999\3025\Information Disclosure Statement.doc

### JC05 Rec'd PCT/PTO 17 JUN 2005

Please type a	plus sign (+) inside this box → [	+	
---------------	-----------------------------------	---	--

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/P	то		Complete if Known			
				Application Number	Unassigned 1/53951		
INFO	RMATION	1 DISC	CLOSURE	Filing Date	June 17, 2005		
STATEMENT BY APPLICANT				First Named Inventor	Timo HEINRICH et al.		
				Group Art Unit	Unassigned		
	(use as many si	heets as n	ecessary)	Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	MERCK-3025		

	U.S. PATENT DOCUMENTS							
	U.S. Patent Document				Date of Publication of Cited Document			
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY			
	1	6251908			June 26, 2001			
	2	5532241			July 2, 1996			
	3	2003040639			February 27, 2003			
	†···							

			Foreign Patent Docu	ment			Pages, Columns, Lines, Where	
Examiner Initials*	Cite No.¹	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Relevant Passages	T <sup>6</sup>
	4	wo	02083666		Boettcher Henning	October 24, 2002		
	5	wo	02102764		Boettcher Henning	December 27, 2002		
.,.	6	wo	9903855		Boettcher Henning	January 28, 1999		Equv to cite 1
	7	wo	0648767		Merck Patent GmbH	April 19, 1995		Equv to cite 2
	8	wo	03087086		Boettcher Henning	October 23, 2003		
	9	wo	0149678		Krog Jensen Christian	July 12, 2001		Equv to cite 3

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside	e this box +
------------------------------------	--------------

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute t	or form 1449A/P	то		Complete if Known ,			
NIE OF	384 A TIOS	i Dicol	OCUDE	Application Number	Complete if Known , 5 3 9 5 1	ĺ	
	RMATION			Filing Date	June 17, 2005	1	
STAT	EMENT	BY APP	LICANT	First Named Inventor	Timo HEINRICH et al.	ĺ	
				Group Art Unit	Unassigned	l	
(	use as many s	heets as nec	essary)	Examiner Name	Unassigned	ı	
Sheet	2	of	2	Attorney Docket Number	MERCK-3025	'	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т²			
	10	BOMHARD A. et al: "Heteroaromatic modifications in the side chain of specific bradycardic benzazepinones J. MED. CHEM., Bd. 34, -1991 XP002277379.				
			<u>.</u>			
			<del></del>			
	•					
	è					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.